HRT Game-Changer for Women's Health with Sara Hover

FDA Removes Black Box Warning on Estrogen: HRT Game-Changer for Women's Health After 23 years, the FDA removed the black box warning on estrogen products—a landmark decision transforming hormone replacement therapy (HRT) for women. In this episode of the Mortar and Pestle podcast, hosts Mike De Lisio and Sebastian Dennison discuss this breakthrough with Sara Hover, Senior Director of Clinical Services at PCCA.   What You'll Learn: Why the 2002 Women's Health Initiative study was flawed and created decades of HRT concerns The timing hypothesis: why age matters when starting hormone replacement therapy Synthetic vs. bioidentical hormones and their clinical differences Oral estrogen delivery systems and safety implications Shared decision-making between patients, prescribers, and pharmacists Why compounded HRT solutions matter for patients who don't fit commercial products Hormone testing modalities and why multiple testing methods are essential Vaginal estrogen's role in preventing UTIs and hip fractures How pharmacists can educate providers and patients on HRT safety   Topics Covered: Black box warning removal, hormone replacement therapy, bioidentical hormones, menopause management, compounding pharmacy, women's health, estrogen, patient monitoring, HRT dosing strategies   Perfect for: Compounding pharmacists, healthcare providers, and anyone seeking evidence-based information on hormone replacement therapy.   Links: The FDA Removes the Black Box Warning on Estrogen: What Pharmacists Need to Know (2025 Update) Why VersaBase Cream Is Your Best Choice for Women's HRT The Vaginal Microbiome, Menopause & HRT A Personalized Approach to HRT for Perimenopausal Women Backed by Science: Anhydrous VersaBase® HRT Optimizing the Patient Experience with the Right HRT Base: Insights from the Webinar